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Abstract
In this updated analysis of patients with relapsed/refractory multiple myeloma (RRMM) from the RandomizEd,
OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Pa-
tients With Relapsed Multiple Myeloma (ENDEAVOR) trial, clinically meaningful overall survival improvements
continue to be observed with carfilzomib 56 mg/m2 and dexamethasone (Kd56; n [ 464) versus bortezomib
and dexamethasone (n [ 465), including in key patient subgroups. With longer-term data, the favorable
benefit-risk profile of Kd56 continues to support its use as a standard-of-care in RRMM.
Introduction: The phase III RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bor-
tezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial showed significantly
improved progression-free survival and overall survival (OS) with carfilzomib (56 mg/m2) and dexamethasone (Kd56)
versus bortezomib and Kd56 (Vd) in patients with relapsed or refractory multiple myeloma (RRMM). We report updated
OS and safety data after 6 months of additional follow-up. Patients and Methods: Patients with RRMM (1-3 previous
lines of therapy) were randomized 1:1 to Kd56 or Vd. Median OS was estimated using the KaplaneMeier method; OS
was compared between treatment groups using Cox proportional hazards models. Results: As of July 19, 2017,
median follow-up was 44.3 months for Kd56 and 43.7 months for Vd. Median OS was 47.8 months (Kd56) versus 38.8
months (Vd; hazard ratio, 0.76; 95% confidence interval, 0.633-0.915). OS was longer with Kd56 versus Vd within age
and cytogenetic subgroups, and according to number of previous lines of therapy, previous bortezomib exposure,
previous lenalidomide exposure, and lenalidomide-refractory status. Exposure-adjusted incidences per 100 patient-
years of adverse events (AEs) were 1352.07 for Kd56 and 1754.86 for Vd; for Grade 3 AEs, these values were
162.31 and 175.90. Conclusion: With median follow-up of approximately 44 months, clinically meaningful improve-
ments in OS were observed with Kd56 versus Vd, including in all subgroups examined. The Kd56 safety profile was
consistent with previous analyses.
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Introduction
As treatment options for multiple myeloma (MM) increase,
treatment paradigms are changing. The use of novel therapies has
resulted in improved outcomes; however, patients with MM usually
relapse1 and improving outcomes obtained with subsequent lines of
therapy, particularly across the heterogeneous relapsed or refractory
MM (RRMM) patient population, remains a challenge. The “gold
standard” therapeutic goal for any agent used in oncology is
extended overall survival (OS).2 To date, only 2 MM clinical trials,
the RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus
DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients
With Relapsed Multiple Myeloma (ENDEAVOR) trial and the
CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalido-
mide and Dexamethasone for the treatment of PatIents with
Relapsed Multiple MyEloma (ASPIRE) trial, have shown a statis-
tically significant improvement in OS beyond that observed using a
recent standard-of-care regimen containing either lenalidomide or
the first-generation proteasome inhibitor (PI) bortezomib.3-5Figure 1 Trial ProfileAt the time of the ENDEAVOR (NCT01568866) study design,
standard therapy for MM that included a PI consisted of fixed-
duration therapy. Fixed-duration therapy is appropriate when
such therapy is curative, or when exposure above a threshold causes
toxicity. Because RRMM is incurable, and the dose-limiting toxicity
for the comparator arm is sensory neuropathy, it was considered
ethical to allow a continuous therapy design. Continuous therapy
with carfilzomib (56 mg/m2) and dexamethasone (Kd56) versus
bortezomib and dexamethasone (Vd), with stratification on the basis
of previous exposure to PI, was deemed balanced. The study design
maximized treatment effect for each agent, allowing a true com-
parison of efficacy of these 2 PIs. The primary end point of
progression-free survival (PFS) and secondary end point of OS were
met.3,4 In a prespecified interim analysis, the median OS was 47.6
months (95% confidence interval [CI], 42.5 to not estimable [NE])
in the Kd56 group versus 40.0 months (95% CI, 32.6-42.3) in the
Vd group (hazard ratio [HR], 0.791; 95% CI, 0.648-0.964; 1-sided
P ¼ .010).3Clinical Lymphoma, Myeloma & Leukemia August 2019 - 523
Figure 2 KaplaneMeier Curve of Overall Survival (Intent-to-
Treat Population). The Curve Was Truncated at the
Time Point When Only 10 Subjects (Kd56 and Vd
Combined) Were at Risk
Abbreviations: HR ¼ hazard ratio; Kd56 ¼ carfilzomib (56 mg/m2) and dexamethasone;
OS ¼ overall survival; Vd ¼ bortezomib and dexamethasone.
Updated Survival and Subgroup Analysis of ENDEAVOR
524 -The ENDEAVOR study remained open to fulfill a postmarket-
ing requirement that the sponsor submits a report of safety and
efficacy outcomes with at least 3 years of follow-up data on long-
term treatment. In July 2017, all ENDEAVOR patients had
received 3 years of follow-up. Herein we report updated exposure
and survival data from the 3-year data cutoff.
Patients and Methods
Study Design and Patients
The ENDEAVOR trial design has been described previously.3,4
Briefly, ENDEAVOR was a phase III, randomized, open-label
study of adult patients with RRMM who had received 1 to 3 pre-
vious lines of therapy.
Patients were randomized 1:1 to receive Kd56 or Vd. Random-
ization was stratified in accordance with several baseline factors:
International Staging System stage (I vs. II-III); lines of previous
treatment (1 vs. 2 or 3 lines); previous PI treatment (previous vs. no
previous carfilzomib or bortezomib treatment); and planned route
of bortezomib administration (intravenous [IV] vs. subcutaneous).
In the Kd56 group, patients received carfilzomib as an IV infu-
sion over 30 minutes on days 1, 2, 8, 9, 15, and 16 of 28-day cycles.
The carfilzomib dose was 20 mg/m2 on days 1 and 2 of cycle 1,
followed by 56 mg/m2 thereafter. Dexamethasone 20 mg was
administered orally or IV on days 1, 2, 8, 9, 15, 16, 22, and 23.
Patients in the Vd group received bortezomib 1.3 mg/m2 as an IV
bolus or subcutaneous injection on days 1, 4, 8, and 11 of each 21-
day cycle. Dexamethasone (20 mg; oral or IV) was administered on
days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment was given until disease
progression, physician decision, unacceptable toxicity, withdrawal ofClinical Lymphoma, Myeloma & Leukemia August 2019consent, or death. Safety follow-up continued for all patients
receiving treatment and through 30 days after treatment
discontinuation.
The institutional review board/ethics committee at each partici-
pating site approved the study, and the protocol conformed to Good
Clinical Practice Guidelines and the principles of the Declaration of
Helsinki. All participants provided written informed consent.
Data Sharing
Qualified researchers may request data from Amgen clinical
studies. Complete details are available at: http://www.amgen.com/
datasharing
Assessments
Cytogenetic analyses were carried out using fluorescence in situ
hybridization (FISH) to determine the risk status of patients. Those
defined as being at “high risk” were patients with the genetic sub-
types t(4;14) or t(14;16) in 10% of screened plasma cells, or with
del(17p) in 20% of screened plasma cells. All other patients with
available and known baseline cytogenetics were included in the
“standard risk” subgroup. Patients with a FISH assessment whose
data could not be analyzed or did not yield a definitive result were
included in the “unknown/missing” cytogenetics subgroup.6
The severity of adverse events (AEs) was classified according to
the National Cancer Institute Common Terminology Criteria for
Adverse Events version 4.03, and AEs were coded according to the
Medical Dictionary for Regulatory Activities (MedDRA) version
20.0. For selected AEs of interest (acute renal failure, cardiac fail-
ure, peripheral neuropathy, ischemic heart disease, and hemato-
poietic thrombocytopenia), standardized MedDRA query narrow
scope (SMQN) grouped terms were applied. Patients who dis-
continued treatment before disease progression were followed-up
every 4 weeks for disease status until progression. After disease
progression, patients were followed for survival status every 3
months.
Outcomes
The primary end point of ENDEAVOR was PFS. Secondary end
points were OS, overall response rate, duration of response, inci-
dence of Grade 2 peripheral neuropathy, and safety. The final
PFS, overall response, and duration of response results were re-
ported in the first interim analysis of ENDEAVOR (data cutoff
November 10, 2014).4 Subsequently, final OS data were reported
from a prospectively planned interim OS analysis (data cutoff
January 3, 2017).3 Herein we report updated OS and safety data
using a more recent data cutoff of July 19, 2017, including OS data
from subgroup analyses. Subgroups included patient age, cytoge-
netic risk group, previous therapy received, and number of lines of
previous treatment.
Statistical Analysis
Median OS was estimated using the KaplaneMeier method. CIs
for the median were estimated using the method by Klein and
Moeschberger with log-log transformation.7 For the comparison of
OS between treatment groups, HRs and corresponding 95% CIs
were estimated using stratified or unstratified Cox proportional
hazards models for the primary intent-to-treat (ITT) population and
Figure 3 KaplaneMeier Curves of Overall Survival (OS) According to Subgroup. (A) Age; (B) Cytogenetic Risk; (C) Number of Previous
Lines of Therapy; (D) Previous Bortezomib Treatment; and (E) Previous Lenalidomide Treatment. The Curves Were Truncated
at the Time Point When Only 10 Subjects (Kd56 and Vd Combined) Were at Risk
Abbreviations: HR ¼ hazard ratio; Kd56 ¼ carfilzomib (56 mg/m2) and dexamethasone; NE ¼ not estimable; Vd ¼ bortezomib and dexamethasone.
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Figure 3 continued
Updated Survival and Subgroup Analysis of ENDEAVOR
526 -subgroup OS analyses, respectively. Exposure-adjusted patient in-
cidences per 100 patient-years were calculated. Total person-time in
each treatment group was the sum of the time to first treatment-
emergent AE for each patient, or the entire time of exposure to
study drug if a patient had no event.
Results
Patients
Between June 20, 2012, and June 30, 2014, 929 eligible patients
were enrolled in ENDEAVOR and randomly assigned to the Kd56
group (n ¼ 464) or the Vd group (n ¼ 465; Figure 1).
Overall Survival
The number of patients alive at the cutoff on July 19, 2017, was
214 (46.1%) in the Kd56 group and 168 (36.1%) in the Vd group.Clinical Lymphoma, Myeloma & Leukemia August 2019Median follow-up time for OS was 44.3 months in the Kd56 group
and 43.7 months in the Vd group. The median OS for the ITT
population was 9.0 months longer in the Kd56 group (median, 47.8
months; 95% CI, 41.9-NE) versus the Vd group (median, 38.8
months; 95% CI, 31.7-42.7), resulting in an HR of 0.76 (95% CI,
0.63-0.92; 1-sided P ¼ .0017; Figure 2).
Subgroup Analyses of OS
KaplaneMeier curves of OS according to patient subgroups are
shown in Figure 3. Median OS was longer in the Kd56 versus Vd
groups, regardless of patient age. In patients aged 75 years, me-
dian OS was 36.1 versus 23.9 months (HR, 0.78; 95% CI, 0.51-
1.20; Kd56, n ¼ 77; Vd, n ¼ 66). For patients aged 65 to 74 years,
median OS was 49.0 versus 36.2 months (HR, 0.71; 95% CI,
0.52-0.96; Kd56, n ¼ 164; Vd, n ¼ 189), and for those aged <65
Figure 3 continued
Robert Z. Orlowski et alyears, median OS was 47.8 versus 42.2 months (HR, 0.79; 95%
CI, 0.60-1.03; Kd56, n ¼ 223; Vd, n ¼ 210). To assess potential
reasons for the greater difference in median OS between treatment
arms in the older patient subgroups compared with the <65-year-
old subgroup, subsequent salvage regimens were evaluated in each
age subgroup. The percentage of patients treated with at least 1
subsequent antimyeloma salvage therapy was similar between
Kd56- versus Vd-treated patients in each age subgroup
(see Supplemental Table 1 in the online version). The percentage of
patients treated with specific antimyeloma salvage therapies,
including lenalidomide, cyclophosphamide, and pomalidomide,
were also similar between Kd56- versus Vd-treated patients across
age subgroups. Bortezomib was the only subsequent antimyeloma
therapy that showed a >10% difference between the Kd56 and Vd
arms within each age group, but these differences were similar
across age groups.Cytogenetic risk status was evaluated for 381/464 (82%) patients
in the Kd56 group and 404/465 (87%) patients in the Vd group.
When assessed according to cytogenetic risk status, median OS was
longer in the Kd56 group versus the Vd group for high-risk patients
(median OS, 28.0 vs. 22.7 months; HR, 0.81; 95% CI, 0.58-1.14;
Kd56, n ¼ 97; Vd, n ¼ 113) and standard-risk patients (median
OS, NE vs. 43.5 months; HR, 0.79; 95% CI, 0.62-1.01; Kd56,
n ¼ 284; Vd, n ¼ 291).
Median OS was longer in the Kd56 group, regardless of the
number of lines of previous therapy received. In patients in the
Kd56 (n ¼ 231) versus Vd (n ¼ 229) groups who had received 1
previous line of therapy, the median OS was 51.3 versus 43.7
months, respectively (HR, 0.77; 95% CI, 0.58-1.02). Similarly, in
patients previously treated with 2 to 3 lines, median OS was 39.5
versus 28.4 months in the Kd56 (n ¼ 233) versus Vd (n ¼ 236)
groups, respectively (HR, 0.75; 95% CI, 0.59-0.96).Clinical Lymphoma, Myeloma & Leukemia August 2019 - 527
Table 1 Summary of Adverse Events in the Safety Population
Kd56 (n [ 463) Vd (n [ 456)
Any Adverse Event, n (%) 457 (98.7) 451 (98.9)
Exposure-Adjusted Incidence of Adverse Events, Rate Per 100 Patient-Years (95% CI) 1352.07 (1233.62-1481.89) 1754.86 (1600.15-1924.53)
Any Grade 3 or Higher Adverse Event, n (%) 379 (81.9) 324 (71.1)
Exposure-Adjusted Incidence of Grade 3 or Higher Adverse Events, Rate Per 100
Patient-Years (95% CI)
162.31 (146.77-179.50) 175.90 (157.75-196.13)
Any Serious Adverse Event, n (%) 279 (60.3) 183 (40.1)
Any Adverse Event Leading to Carfilzomib or Bortezomib Dose Reduction, n (%) 138 (29.8) 226 (49.6)
Any Adverse Event Leading to Treatment Discontinuation, n (%) 137 (29.6) 121 (26.5)
Any Adverse Event Leading to Death, n (%) 32 (6.9) 22 (4.8)
Abbreviations: Kd56 ¼ carfilzomib (56 mg/m2) and dexamethasone; Vd ¼ bortezomib and dexamethasone.
Updated Survival and Subgroup Analysis of ENDEAVOR
528 -Median OS was longer in the Kd56 group versus the Vd
group, regardless of previous exposure to bortezomib. Median OS
for the Kd56 group versus the Vd group was 41.8 versus 32.7
months (HR, 0.85; 95% CI, 0.67-1.08) for patients with pre-
vious bortezomib exposure (Kd56, n ¼ 250; Vd, n ¼ 252) and
NE versus 42.2 months (HR, 0.66; 95% CI, 0.50-0.88) for
patients without previous bortezomib exposure (Kd56, n ¼ 214;
Vd, n ¼ 213).
Median OS was longer in the Kd56 group compared with the Vd
group regardless of previous exposure to lenalidomide. Median OS
for the Kd56 group versus the Vd group was 35.4 versus 29.4
months (HR, 0.88; 95% CI, 0.67-1.16) for patients with previous
lenalidomide exposure (Kd56, n ¼ 177; Vd, n ¼ 178) and 51.3
versus 42.2 months (HR, 0.68; 95% CI, 0.54-0.88) for those
without previous lenalidomide exposure (Kd56, n ¼ 287; Vd, n ¼
287). Median OS was also longer in the Kd56 group versus the Vd
group regardless of whether or not patients were refractory to anyTable 2 Treatment-Emergent Adverse Events in the Safety Populati
Kd56 (n
All Grades







Events of Interest, n (%)
Cardiac failure (SMQN) 51 (11.0)
Ischemic heart disease (SMQN) 18 (3.9)
Peripheral neuropathy (SMQN) 97 (21.0)
Acute renal failure (SMQN) 50 (10.8)
Hematopoietic thrombocytopenia (SMQN) 148 (32.0)
Neutropenia (PT) 29 (6.3)
Abbreviations: Kd56 ¼ carfilzomib (56 mg/m2) and dexamethasone; PT ¼ preferred term; SMQN ¼
and dexamethasone.
aAdverse events (preferred terms) are included if reported in 30% of patients in either treatment
Clinical Lymphoma, Myeloma & Leukemia August 2019previous lenalidomide treatment for MM. Median OS for the
Kd56 group versus the Vd group was 29.2 versus 21.4 months
(HR, 0.86; 95% CI, 0.62-1.18) for lenalidomide-refractory
patients (Kd56, n ¼ 113; Vd, n ¼ 123) and NE versus 42.8
months (HR, 0.74; 95% CI, 0.59-0.93) for those who were not
refractory to a previous lenalidomide treatment (Kd56, n ¼ 351;
Vd, n ¼ 342).
Safety
Overall, 457 (98.7%) patients in the Kd56 group and 451
(98.9%) patients in the Vd group experienced an AE (Table 1).
Exposure-adjusted patient incidence per 100 patient-years of AEs
overall were 1352.07 (95% CI, 1233.62-1481.89) for the Kd56
group and 1754.86 (95% CI, 1600.15-1924.53) for the Vd
group. Grade 3 AEs occurred in 379 (81.9%) patients in the
Kd56 group and 324 (71.1%) in the Vd group (exposure-adjusted
patient incidence per 100 patient-years were 162.31 [95% CI,on
[ 463) Vd (n [ 456)
Grade 3 or Higher All Grades Grade 3 or Higher
80 (17.3) 130 (28.5) 46 (10.1)
19 (4.1) 185 (40.6) 40 (8.8)
14 (3.0) 70 (15.4) 3 (0.7)
69 (14.9) 46 (10.1) 15 (3.3)
32 (6.9) 140 (30.7) 35 (7.7)
29 (6.3) 62 (13.6) 10 (2.2)
28 (6.0) 16 (3.5) 9 (2.0)
12 (2.6) 9 (2.0) 7 (1.5)
11 (2.4) 249 (54.6) 44 (9.6)
27 (5.8) 29 (6.4) 16 (3.5)
58 (12.5) 123 (27.0) 67 (14.7)
12 (2.6) 26 (5.7) 10 (2.2)
standardized Medical Dictionary for Regulatory Activities query, narrow scope; Vd ¼ bortezomib
group.
Table 3 Treatment-Emergent Adverse Events Over Time in the Safety Population

















Any Grade 3 or
Higher Adverse
Event, n (%)
343 (74.1) 306 (67.1) 112 (52.8) 44 (42.3) 42 (47.2) 15 (36.6) 27 (54.0) 7 (28.0)
Abbreviations: Kd56 ¼ carfilzomib (56 mg/m2) and dexamethasone; Vd ¼ bortezomib and dexamethasone.
Robert Z. Orlowski et al146.77-179.50] and 175.90 [95% CI, 157.75-196.13],
respectively).
The most commonly occurring AEs and AEs of interest are
shown in Table 2. Grade 3 cardiac failure (SMQN) occurred in
28 (6.0%) patients in the Kd56 group and 9 (2.0%) in the Vd
group. Cardiac failure (SMQN) led to carfilzomib or bortezomib
dose reduction in 8 (1.7%) patients in the Kd56 group and no
patient in the Vd group. Cardiac failure (SMQN) led to discon-
tinuation of any treatment in 18 (3.9%) patients in the Kd56 group
and 4 (0.9%) patients in the Vd group.
Grade 3 hypertension was reported in 69 (14.9%) patients in the
Kd56 group and 15 (3.3%) patients in the Vd group. Hypertension
led to reduction of carfilzomib dose in 11 (2.4%) patients in the
Kd56 group and no patient in the Vd group. No patient in either
treatment group discontinued carfilzomib or bortezomib treatment
because of hypertension.
Grade 2 peripheral neuropathy (SMQN) was reported in 32
(6.9%) patients in the Kd56 group and 159 (34.9%) in the Vd group.
Peripheral neuropathy (SMQN) led to carfilzomib dose reduction in
9 (1.9%) patients in the Kd56 group and bortezomib dose reduction
in 142 (31.1%) patients in the Vd group. Peripheral neuropathy
(SMQN) led to discontinuation of any treatment in 2 (0.4%) patients
in the Kd56 group and 40 (8.8%) patients in the Vd group.
Infections and infestations (system organ class) were reported in
368 (79.5%) patients in the Kd56 group and 319 (70.0%) patients
in the Vd group. Grade 3 AEs in this class were reported in 148
(32.0%) patients and 94 (20.6%) patients, respectively.
The incidence of Grade 3 AEs decreased over time in both
treatment groups (Table 3). In total, 343 (74.1%) patients of 463
receiving Kd56 experienced a Grade 3 AE between 0 to 12
months, 112 (n ¼ 212; 52.8%) within 12 to 24 months, 42 (n ¼
89; 47.2%) between 24 to 36 months, and 27 (n ¼ 50; 54.0%)
beyond 36 months of treatment. A total of 306 (67.1%) of 456
patients receiving Vd reported grade 3 AEs from 0 to 12
months, 44 (n ¼ 104; 42.3%) between 12 to 24 months, 15 (n ¼
41; 36.6%) between 24 to 36 months, and 7 (n ¼ 25; 28.0%)
beyond 36 months from Vd start date.
At 36 months, 35 patients (7.5%) in the Kd56 group and 21
patients (4.5%) in the Vd group were still receiving treatment.
Discussion
The phase III ENDEAVOR trial evaluated the efficacy and safety
of Kd56 versus Vd in patients with RRMM. The initial publications
from ENDEAVOR reported significant improvements in OS (21%
reduction in the risk of death), PFS, and responses for patientsreceiving treatment with Kd56 versus Vd.3,4 In the present analysis
with longer follow-up (median follow-up of approximately 44
months), OS results continued to show improvement with Kd56
versus Vd (median OS, 47.8 vs. 38.8 months; HR, 0.76; 95% CI,
0.63-0.92; 1-sided P ¼ .0017).
In the interim OS analysis, treatment with Kd56 also improved
OS across several patient subgroups,3 and this continues with an
additional 6 months of follow-up. For patient subgroups according
to previous lines of therapy, previous bortezomib exposure, previous
lenalidomide exposure, and lenalidomide-refractory status, there was
a 12% to 34% reduction in the risk of death for the Kd56 group
versus the Vd group. Across all age and cytogenetic subgroups, an
OS benefit was shown for Kd56 versus Vd, including in elderly
patients (75 years) and patients with high-risk cytogenetics.
Late phase clinical trials include measures of clinical benefit that
support regulatory approval. Although measurement of OS requires
prolonged trials, and OS outcomes might be confounded by the
availability of active therapeutics used in later lines, OS remains the
oncology end point preferred by the European Medicines Agency,
the Food and Drug Administration, and other health authorities for
regulatory approval.
The safety data obtained during this analysis were consistent with
those previously reported from the first and final analyses of
ENDEAVOR.3,4 The exposure-adjusted incidence per 100 patient-
years of AEs was lower in patients treated with Kd56 than Vd
(1352.07 vs. 1754.86). Although the number of patients with re-
ported Grade 3 AEs was higher with carfilzomib than with bor-
tezomib (379 [81.9%] and 324 [71.1%] for Kd56 vs. Vd,
respectively), the exposure-adjusted incidence of Grade 3 AEs was
also lower in the Kd56 group than in the Vd group (162.31 vs.
175.90). Overall, the long-term safety profile for Kd56 was
acceptable, and there has been no evidence of cumulative toxicity
with extended treatment.
Because of the relapsing nature of MM, and the availability of
well tolerated agents, prolonged courses of maintenance therapy are
now a standard of care in myeloma. Because maintenance lenali-
domide confers a PFS and possibly an OS advantage compared with
placebo in treatment of first-line MM8-10 and when lenalidomide-
dexamethasone is compared with dexamethasone,11,12
lenalidomide-dexamethasone is becoming a standard first-line
treatment, and therefore might not be an option for patients at
relapse.10 The ENDEAVOR trial was designed to offer RRMM
patients an alternate doublet therapy until progression or intoler-
ance. These results, showing tolerability and a survival benefit,
support the emerging role of prolonged PI therapy.Clinical Lymphoma, Myeloma & Leukemia August 2019 - 529
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530 -Conclusion
With additional follow-up, clinically meaningful OS improve-
ments continue to be observed with Kd56 versus Vd, including in
key patient subgroups. The benefit-risk profile of Kd56 with longer-
term data continued to provide support for its use as a standard of
care in patients with RRMM.
Clinical Practice Points
 Extending OS is a major therapeutic goal for MM agents. PIs,
such as bortezomib or carfilzomib, are a backbone therapy in
MM treatment.
 In a prespecified interim analysis (data cutoff January 3, 2017) of
the randomized phase III ENDEAVOR study, Kd56 signifi-
cantly improved OS over Vd in patients with RRMM.
 Herein we report updated ENDEAVOR OS and safety data
using a more recent data cutoff of July 19, 2017, when all pa-
tients had received at least 3 years of follow-up.
 Median OS was extended by 9 months with Kd56 versus Vd.
These OS benefits were consistent across all subgroups exam-
ined, including patient age, cytogenetic risk, previous lenalido-
mide exposure, and lenalidomide-refractory status.
 Safety data were consistent with previous analyses.
 These longer-term data continue to provide support for the use
of Kd56 as a standard of care in patients with RRMM.Acknowledgments
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Supplemental Table 1 Subsequent Antimyeloma Therapies According to Age Group in ‡10% of Patients (ITT Population)
<65 Years 65-74 Years ‡75 Years
Kd56 (n [ 223) Vd (n [ 210) Kd56 (n [ 164) Vd (n [ 189) Kd56 (n [ 77) Vd (n [ 66)
Patients Treated
With at Least 1
Antimyeloma
Therapy, n (%)
150 (67.3) 143 (68.1) 101 (61.6) 125 (66.1) 40 (51.9) 33 (50.0)
Dexamethasone 110 (49.3) 115 (54.8) 71 (43.3) 92 (48.7) 28 (36.4) 23 (34.8)
Lenalidomide 77 (34.5) 87 (41.4) 44 (26.8) 62 (32.8) 16 (20.8) 16 (24.2)
Cyclophosphamide 53 (23.8) 65 (31.0) 34 (20.7) 35 (18.5) 12 (15.6) 14 (21.2)
Pomalidomide 43 (19.3) 50 (23.8) 29 (17.7) 47 (24.9) 10 (13.0) 10 (15.2)
Bortezomib 59 (26.5) 32 (15.2) 44 (26.8) 20 (10.6) 15 (19.5) 5 (7.6)
Melphalan 29 (13.0) 32 (15.2) 19 (11.6) 20 (10.6) 5 (6.5) 4 (6.1)
Thalidomide 27 (12.1) 34 (16.2) 9 (5.5) 23 (12.2) 3 (3.9) 3 (4.5)
Prednisone 8 (3.6) 11 (5.2) 10 (6.1) 20 (10.6) 4 (5.2) 5 (7.6)
Abbreviations: ITT ¼ intent-to-treat; Kd56 ¼ carfilzomib (56 mg/m2) and dexamethasone; Vd ¼ bortezomib and dexamethasone.
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